Bank of America Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price increased by equities research analysts at Bank of America from $13.00 to $15.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. Bank of America's price target points to a potential upside of 67.69% from the stock's previous close.

BCRX has been the subject of a number of other reports. Needham & Company LLC reissued a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, June 28th. Wedbush raised their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday. Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX traded down $0.08 during trading on Tuesday, reaching $8.95. The stock had a trading volume of 1,407,127 shares, compared to its average volume of 3,032,538. The stock has a market capitalization of $1.87 billion, a PE ratio of -34.40, a P/E/G ratio of 2.55 and a beta of 1.04. BioCryst Pharmaceuticals has a 52 week low of $6.02 and a 52 week high of $11.31. The business's 50-day moving average price is $10.06 and its 200 day moving average price is $8.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. GF Fund Management CO. LTD. bought a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $33,000. GAMMA Investing LLC boosted its stake in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth $79,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.